We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Use of the Moderna COVID-19 vaccine or ‘Spikevax’ has been approved for 6 to 11s after meeting the required safety, quality and effectiveness standards
The government announces its intention to introduce a licensing regime for non-surgical cosmetic procedures such as Botox and fillers.
First published during the 2019 to 2022 Johnson Conservative government
A reflection by Dr June Raine, Chief Executive of the Medicines and Healthcare products Regulatory Agency
This monoclonal antibody – the second to be authorised by the Medicines and Healthcare products Regulatory Agency – is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
The antiviral was found to be safe and effective following a stringent review of the available evidence.
AWTTC joins the Innovative Licensing and Access Pathway as a permanent partner
Regulatory updates by the MHRA today on the COVID-19 booster vaccine programme for winter 2021 to 2022
The regulatory changes made by the MHRA today give further options for the deployment programme.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today given approval for the first monoclonal antibody treatment for the prevention and treatment of COVID-19 in the UK.
The UK regulator has confirmed the vaccine is safe and effective in this age group.
This follows a rigorous review of the safety, quality and effectiveness of the vaccine in this age group.
The vaccine has been approved after meeting the required safety, quality and effectiveness standards.
Change approved following detailed review of additional stability data
The MHRA is committed to speeding up access to innovative new medicines for patients.
Future vaccine modifications that respond to new variants of coronavirus to be made available quickly to UK recipients, without compromising on safety, quality or effectiveness.
The Innovative Licensing and Access Pathway (ILAP) aims to reduce the time to market for innovative medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP).
MHRA Chief Executive Dr June Raine explains the process behind the Agency's approval of the Pfizer/BioNTech vaccine
MHRA has today given the first positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for use of Gilead’s remdesivir.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).